Lumican is overexpressed in lung adenocarcinoma pleural effusions

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Cappellesso, Rocco ^a   Millioni, Renato ^a   Arrigoni, Giorgio ^a   Simonato, Francesca ^a   Caroccia, Brasilina ^a   Iori, Elisabetta ^a   Guzzardo, Vincenza ^a   Ventura, Laura ^a   Tessari, Paolo ^a   Fassina, Ambrogio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LUMICAN; KERATAN SULFATE; LUM PROTEIN, HUMAN; PROTEOCHONDROITIN SULFATE; PROTEOME;

ARTICLE; CELL LYSATE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; FEMALE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTIFICATION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; ADENOCARCINOMA; CANCER GRADING; CANCER STAGING; GENETICS; LUNG TUMOR; MALIGNANT PLEURA EFFUSION; METABOLISM; PATHOLOGY; PROCEDURES; PROTEOMICS; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE, TUMOR; CHONDROITIN SULFATE PROTEOGLYCANS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATAN SULFATE; LUMICAN; LUNG NEOPLASMS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PLEURAL EFFUSION, MALIGNANT; PROTEOME; PROTEOMICS;

EID: 84930623703     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126458     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29. doi: 10.3322/caac.21208 PMID: 24399786
2. Travis WD, Brambilla E, Muller-Hermelink H, Harris CC. World Health Organization classification of tumours. Pathology and genetics. Tumours of the lung, pleura, thymus and heart. Lyon: IARC press; 2004.
3. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res. 2004; 3(2):179-196. PMID: 15113093
4. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006; 24(8):971-983. PMID: 16900146
5. Pastor MD, Nogal A, Molina-Pinelo S, Carnero A, Paz-Ares L. Proteomic biomarkers in lung cancer. Clin Transl Oncol. 2013; 15:671-682. doi: 10.1007/s12094-013-1034-0 PMID: 23606351
6. Millioni R, Tolin S, Puricelli L, Sbrignadello S, Fadini GP, Tessari P, et al. High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. PLoS One. 2011; 6:e19603. doi: 10.1371/journal.pone.0019603 PMID: 21573190
7. Millioni R, Tolin S, Fadini GP, Falda M, van Breukelen B, Tessari P, et al. High confidence and sensitivity four-dimensional fractionation for human plasma proteome analysis. Amino Acids. 2012; 43:2199-2202. doi: 10.1007/s00726-012-1267-1 PMID: 22434181
8. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002; 1:845-867. PMID: 12488461
9. Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972; 77:507-513. PMID: 4642731
10. Menegazzo L, Albiero M, Millioni R, Tolin S, Arrigoni G, Poncina N, et al. Circulating myeloid calcifying cells have antiangiogenic activity via thrombospondin-1 overexpression. FASEB J. 2013; 27:4355-4365. doi: 10.1096/fj.12-223719 PMID: 23901071
11. Gauci S, van Breukelen B, Lemeer SM, Krijgsveld J, Heck AJ. A versatile peptide pI calculator for phosphorylated and N-terminal acetylated peptides experimentally tested using peptide isoelectric focusing. Proteomics. 2008; 8:4898-4906. doi: 10.1002/pmic.200800295 PMID: 19003858
12. Rosato A, Menin C, Boldrin D, Dalla Santa S, Bonaldi L, Scaini MC, et al. Survivin expression impacts prognostically on NSCLC but not SCLC. Lung Cancer. 2013; 79:180-186. doi: 10.1016/j.lungcan.2012.11.004 PMID: 23218791
13. Cappellesso R, Tinazzi A, Giurici T, Simonato F, Guzzardo V, Ventura L, et al. Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. Cancer Cytopathol. 2014; 122:685-693. doi: 10.1002/cncy.21442 PMID: 24888238
14. Marioni G, Nucci R, Marino F, Cappellesso R, Pillon M, Zanoletti E, et al. Evaluation of the prognostic role of pSTAT3 expression in temporal bone squamous cell carcinoma. Otol Neurotol. 2013; 34:1476-1482. doi: 10.1097/MAO.0b013e3182a036c9 PMID: 24005169
15. Iori E, Millioni R, Puricelli L, Arrigoni G, Lenzini L, Trevisan R, et al. Glycolytic enzyme expression and pyruvate kinase activity in cultured fibroblasts from type 1 diabetic patients with and without nephropathy. Biochim Biophys Acta. 2008; 1782:627-633. doi: 10.1016/j.bbadis.2008.08.012 PMID: 18840520
16. Brezillon S, Pietraszek K, Maquart FX, Wegrowski Y. Lumican effects in the control of tumour progression and their links with metalloproteinases and integrins. FEBS J. 2013; 280:2369-2381. doi: 10.1111/febs.12210 PMID: 23438179
17. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med. 2011; 15:1013-1031. doi: 10.1111/j.1582-4934.2010.01236.x PMID: 21155971
18. Nikitovic D, Papoutsidakis A, Karamanos NK, Tzanakakis GN. Lumican affects tumor cell functions, tumor-ECM interactions, angiogenesis and inflammatory response. Matrix Biol. 2014; 35:206-214. doi: 10.1016/j.matbio.2013.09.003 PMID: 24060754
19. Morgensztern D, Waqar S, Subramanian J, Trinkaus K, Govindan R. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012; 7:1485-1489. doi: 10.1097/JTO.0b013e318267223a PMID: 22982649
20. Donnem TP, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, et al. Stromal CD8+ T Cell Density - A Promising Supplement to TNM staging in Non-Small Cell Lung Cancer. Clin Cancer Res 2015. In press.
21. Dolhnikoff M, Morin J, Roughley PJ, Ludwig MS. Expression of lumican in human lungs. Am J Respir Cell Mol Biol. 1998; 19:582-587. PMID: 9761754
22. McEwan PA, Scott PG, Bishop PN, Bella J. Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. J Struct Biol. 2006; 155:294-305. PMID: 16884925
23. Schaefer L, Iozzo RV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem. 2008; 283:21305-21309. doi: 10.1074/jbc.R800020200 PMID: 18463092
24. Stamov DR, Muller A, Wegrowski Y, Brezillon S, Franz CM. Quantitative analysis of type I collagen fibril regulation by lumican and decorin using AFM. J Struct Biol. 2013; 183:394-403. doi: 10.1016/j.jsb.2013.05.022 PMID: 23747391
25. Vij N, Roberts L, Joyce S, Chakravarti S. Lumican regulates corneal inflammatory responses by modulating Fas-Fas ligand signaling. Invest Ophthalmol Vis Sci. 2005; 46:88-95. PMID: 15623759
26. Vuillermoz B, Khoruzhenko A, D'Onofrio MF, Ramont L, Venteo L, Perreau C, et al. The small leucinerich proteoglycan lumican inhibits melanoma progression. Exp Cell Res. 2004; 296:294-306. PMID: 15149859
27. Albig AR, Roy TG, Becenti DJ, Schiemann WP. Transcriptome analysis of endothelial cell gene expression induced by growth on matrigel matrices: identification and characterization of MAGP-2 and lumican as novel regulators of angiogenesis. Angiogenesis. 2007; 10:197-216. PMID: 17632767
28. Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 2006; 4:38. PMID: 17190588
29. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012; 196:395-406. doi: 10.1083/jcb.201102147 PMID: 22351925
30. Matsuda Y, Yamamoto T, Kudo M, Kawahara K, Kawamoto M, Nakajima Y, et al. Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma. Int J Oncol. 2008; 33:1177-1185. PMID: 19020750